An enzyme immunoassay was developed for quantification of tenascin in biologic samples. An enzyme conjugate prepared by coupling peroxidase to a well-characterized, affinity-purified monoclonal antibody EB2 to human tenascin was used as principal reagent. The assay comprises 96-well microtitration s
Bioassay vs. immunoassay for quantification of interleukin-6 in biological fluids
โ Scribed by Nikolaos G. Papadopoulos; George V. Z. Dedoussis; Constantin N. Baxevanis; Michail Papamichail
- Book ID
- 102308575
- Publisher
- John Wiley and Sons
- Year
- 1995
- Tongue
- English
- Weight
- 420 KB
- Volume
- 9
- Category
- Article
- ISSN
- 0887-8013
No coin nor oath required. For personal study only.
โฆ Synopsis
As several possible prognostic and therapeutic applications of interleukin-6 are currently under trial, the available methods for its quantification in biological fluids should be evaluated. In this report, the 7TD1 hybridoma bioassay is compared to an enzyme immunoassay for the determination of interleukin-6 in serum and plasma of normal subjects and patients with cancer, sepsis, and systemic lupus erythematosus, as well as in malignant pleural effusions and culture supernatants. The results show a good correlation between the two methods in all cases. Mean values of the examined groups were statistically different between the assays only in the case of septic patients. This may be attributed either to the influence of other molecules on the assays or to the nonlinearity of the dose-response curves. Since immunoassays are easier to perform, it seems that they are more suitable for routine use, the bioassay being preferable in cases where increased sensitivity is required.
๐ SIMILAR VOLUMES
An enzyme-linked immunosorbent assay (ELISA) of bronchial inhibitor using rabbit antibronchial inhibitor antibody-coated polystyrene balls as the solid-phase antibody and peroxidaselabeled antibody as the conjugate is described. A crude antibody fraction is used for coating the solid phase. The assa
## Abstract The study of pharmacologically active peptides is central to the understanding of disease and development of novel therapies. It would be advantageous to monitor the fate of bioactive peptides in biological fluids and tissues following their __in vivo__ administration (exogenous adminis